MRI vendor Fonar is back in the black for the first time sinceMarch 1994. The Melville, NY, company posted financial resultsfor its third fiscal quarter (end-March) that show net incomeof $1.9 million, compared with a net loss of $903,000 in the
MRI vendor Fonar is back in the black for the first time sinceMarch 1994. The Melville, NY, company posted financial resultsfor its third fiscal quarter (end-March) that show net incomeof $1.9 million, compared with a net loss of $903,000 in the sameperiod last year. The growth in profits came as Fonar's revenuesslipped to $3 million in the most recent quarter, compared with$3.2 million in the third quarter of 1995.
Fonar did not indicate how it was able to record such a rapidprofit turnaround on lower sales. It is possible that the companyis enjoying the benefits of payments related to MRI patent litigationit has settled with Hitachi and Philips, but Fonar declined tostate whether it received any such payments in its most recentquarter.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.